Premium
The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy
Author(s) -
Bahrami Afsane,
Hasanzadeh Malihe,
Hassanian Seyed Mahdi,
ShahidSales Soodabeh,
GhayourMobarhan Majid,
Ferns Gordon A.,
Avan Amir
Publication year - 2017
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26118
Subject(s) - pi3k/akt/mtor pathway , cervical cancer , medicine , biomarker , protein kinase b , malignancy , cancer , oncology , cancer research , bioinformatics , signal transduction , biology , biochemistry
Cervical cancer is a common gynecological cancer and a leading cause of cancer‐related death in women globally. There is a need for the identification of prognostic and predictive biomarker for risk stratification. The phosphatidylinositol 3‐kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is often dysregulated in cervical cancer, indicating that it may be a potential therapeutic target in the treatment of this malignancy, and could perhaps be used as a novel biomarker in the assessment of risk of developing cervical cancer. We aimed to provide an overview of the potential applications of the PI3K/Akt/mTOR pathway as biomarker for risk stratification, in predicting the prognosis of cervical cancer, and for developing new therapeutic approaches in patients with cervical cancer. J. Cell. Biochem. 118: 4163–4169, 2017. © 2017 Wiley Periodicals, Inc.